まとめ
Diltiazemは,安定したアンギナを持つ患者のアンギナ発作を効果的に軽減しました. ディルチアゼムとプロプラノロールを併用すると,プロプラノロール単独と比較して,運動耐性がさらに向上し,アンギナ発症率が低下しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- 安定した angina pectorisは,一般的な心血管疾患です.
- 現在の治療法は,心筋の酸素需要を減らし,酸素供給を改善することを目的としています.
研究 の 目的:
- 安定したアンギナを持つ患者のカルシウムチャネルブロッカーであるディルティアゼムの有効性を評価する.
- 胸痛の症状と運動能力に対するディルチアゼムとベータブロッカーであるプロプラノロールの加分効果を評価する.
主な方法:
- 14週間のクロスオーバー試験で,安定したアンギナを持つ24人の患者が参加しました.
- 連続した治療期間は,プラセボ,ディルチアゼム,プロプロノロール,および併用療法 (ディルチアゼム + プロプロノロール) を含む.
- 投与量は,最大許容レベルまたは臨床β-ブロックに定位されました.
主要な成果:
- ディルティアゼムは,毎日のアンギナ発作率を1.6から0.6に大幅に低下させた (p < .005).
- 併用療法 (ディルティアゼム + プロプラノロール) は,プロプラノロール単独 (0.6) またはプラセボ (0.5) (p < .01) と比較して,アンギナ率 (0.3) をさらに改善しました.
- ディルチアゼム,プロプラノロール,特に併用療法では運動期間が増加しました.
結論:
- ディルチアゼム単独療法では,安定した心筋梗塞の管理に有効です.
- ディルチアゼムとプロプラノロルの併用療法は,アンギナ発症の頻度を低減し,運動耐性を向上させる上で優れた利点を提供します.
- 閉塞性心不全などの有害事象の注意深いモニタリングは,特にエジェクション分子が減少した患者の場合,正当化されています.
さらに関連する動画
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
関連する概念動画
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
